Awake Axillary Impella 5.5 Placement - A Feasibility Trial

Sponsor
University of Pennsylvania (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05782491
Collaborator
Abiomed Inc. (Industry)
10
2
1
12
5
0.4

Study Details

Study Description

Brief Summary

The Abiomed Impella 5.5 is a surgically placed temporary mechanical support device used in patients in cardiogenic shock. The investigators propose using regional anesthesia (3 separate peripheral nerve blocks) to facilitate Impella 5.5 placement, a procedure which has traditionally been performed under a general anesthetic.

Regional anesthesia is a proven and widely used technique to facilitate upper extremity vascular surgery cases (i.e. arteriovenous fistula creation). The investigators believe that employing these blocks in conjunction with intravenous sedation or monitored anesthesia care (MAC anesthesia) - a technique used in all types of cases, even in sick hearts during thranscatheter aortic valve replacements (TAVR) - will avoid the need increased doses of medications to support the blood pressure and cardiac output, avoid the need for post operative mechanical ventilation and intravenous sedation, and speed up the time to participating in physical therapy, time to heart transplant/durable mechanical support/recovery, and time to hospital discharge.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Interscalene Block
  • Procedure: PECS II Block
  • Procedure: Superficial Cervical Plexus Block
N/A

Detailed Description

General anesthesia places patients who are in cardiogenic shock at risk for life threatening hemodynamic compromise due to the anesthetic and positive pressure ventilation, and confers the need for mechanical ventilation and sedation post operatively.

Our hypothesis is that by utilizing regional anesthesia, anesthesiologists can facilitate surgical Impella placement with less risk of cardiovascular collapse with a faster road to recovery. By avoiding endotracheal intubation and concomitant heavy sedation both in the operating room and ICU, these patients will avoid worsening deconditioning and ICU delirium, with less days to physical therapy, ambulation, and recovery as compared to patients who undergo general anesthesia and remain ventilated in the ICU after their Impella placement.

Patients scheduled for Impella 5.5 placement will be screened by a specific set of inclusion/exclusion criteria for potential participation in the study. If they consent, they will receive three commonly used upper extremity nerve blocks (Interscalene, PECS II, and superficial cervical plexus nerve blocks) and receive only intravenous sedation during the procedure.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
10 patients in cardiogenic shock listed for Impella 5.5 placement10 patients in cardiogenic shock listed for Impella 5.5 placement
Masking:
None (Open Label)
Masking Description:
No blinding in this study
Primary Purpose:
Treatment
Official Title:
Rapid Progression of Care in Cardiogenic Shock - Awake Surgical Placement of the Impella 5.5 Using Regional Anesthesia
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment Arm

Patient in cardiogenic shock listed for Impella 5.5 placement who meets study inclusion criteria

Procedure: Interscalene Block
It is an ultrasound guided brachial plexus nerve block at roots/trunks used to anesthetize the shoulder and upper arm. Goal is to spread local anesthetic around superior and middle trunks of brachial plexus, between the anterior and middle scalene muscles.
Other Names:
  • Peripheral nerve block
  • Procedure: PECS II Block
    PECS II block is comprised of two separate fascial plane blocks to anesthetize anterolateral chest wall using an ultrasound guided injection between the pectoralis major muscle and pectoralis minor muscle at third rib and a second ultrasound guided injection between pectoralis minor and serratus anterior. The goal is a high volume hydro dissection of the two fascial planes to anesthetize anterolateral chest wall and axilla.
    Other Names:
  • Pectoral Block
  • Peripheral nerve block
  • Fascial plane block
  • Procedure: Superficial Cervical Plexus Block
    This block is a superficial injection to the deep cervical fascia between the investing layer of the deep cervical fascia and the prevertebral fascia in the neck. This block provides anesthesia of the skin of the anterolateral neck and the ante-auricular and retro-auricular areas, as well as the skin overlying and immediately inferior to the clavicle on the chest wall. This is an ultrasound guided injection with the goal of placing the needle tip in the fascial layer underneath the SCM adjacent to the cervical plexus, which is contained within the tissue space between the Cervical fascia and posterior sheath of the SCM.
    Other Names:
  • Cervical plexus block
  • Peripheral nerve block
  • Outcome Measures

    Primary Outcome Measures

    1. Success of Using Regional Anesthesia for Impella 5.5 Placement [Day of procedure (1 day)]

      Number of patients that successfully undergo Impella 5.5. placement with the regional anesthesia protocol

    Secondary Outcome Measures

    1. Time to participation in physical therapy [6 weeks]

      Time from end of operation to getting out of bed or involving in physical therapy sessions

    2. Time to destination therapy [6 weeks]

      Time to decision of heart transplant, ventricular assist device, or recovery

    3. Sedation requirement [1 week]

      Total dose of sedatives required post operatively

    4. Pain medication requirement [1 week]

      Total dose of pain medication required post operatively

    5. Patient pain scores post operatively [3 days]

      The Numeric Pain Rating Scale score on post operative evaluations

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    Baseline Criteria:
    • Agrees to procedure

    • Excellent ultrasound images for nerve blocks

    • Excellent ultrasound images for trans thoracic echo

    • Age <60, BMI <30

    • Non hostile neck

    • Evaluation of CT amenable to easy surgical access for Impella placement

    Meets criteria for MAC sedation:
    • Able to lay relatively flat comfortably

    • Able to understand and cooperate with procedures

    • Easy airway (Mallampati I - II, prior grade 1-2 airway)

    • Low risk of airway obstruction

    • No high baseline oxygen requirement (over 6L/min)

    Meets criteria for regional anesthesia:
    • Patient agrees to nerve block

    • No active areas of infection around the block site

    • No history of nerve damage or deficits in the area of the proposed nerve block

    • No contralateral diaphragmatic paralysis or phrenic nerve palsy

    Exclusion Criteria:
    • Does not wish to have MAC

    • Does not wish to have Regional Anesthesia

    • BMI > 30

    • Poor U/S windows for block or TTE

    • Active infection over block area

    • High Oxygen Requirement >6L NC

    • Known or anticipated difficult airway

    • Unable to lay flat comfortably Unable to cooperate or follow instructions

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital of the University of Pennsylvania Philadelphia Pennsylvania United States 19104
    2 Penn Presbyterian Medical Center Philadelphia Pennsylvania United States 19104

    Sponsors and Collaborators

    • University of Pennsylvania
    • Abiomed Inc.

    Investigators

    • Principal Investigator: Asad Usman, MD, MPH, University of Pennsylvania
    • Principal Investigator: Marisa Cevasco, MD, MPH, University of Pennsylvania

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Pennsylvania
    ClinicalTrials.gov Identifier:
    NCT05782491
    Other Study ID Numbers:
    • 852788
    • 77327727
    First Posted:
    Mar 23, 2023
    Last Update Posted:
    Mar 23, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Pennsylvania
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 23, 2023